SEC Info℠ | Home | Search | My Interests | Help | Sign In | Please Sign In | ||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 4/16/24 Oncocyte Corp. 10-K 12/31/23 87:30M M2 Compliance LLC/FA |
Document/Exhibit Description Pages Size 1: 10-K Annual Report HTML 2.10M 2: EX-4.13 Instrument Defining the Rights of Security Holders HTML 34K 5: EX-10.28 Material Contract HTML 35K 6: EX-10.29 Material Contract HTML 35K 7: EX-10.30 Material Contract HTML 35K 3: EX-23.1 Consent of Expert or Counsel HTML 24K 4: EX-23.2 Consent of Expert or Counsel HTML 24K 11: EX-97.1 Clawback Policy re: Recovery of Erroneously HTML 37K Awarded Compensation 8: EX-31.1 Certification -- §302 - SOA'02 HTML 31K 9: EX-31.2 Certification -- §302 - SOA'02 HTML 30K 10: EX-32.1 Certification -- §906 - SOA'02 HTML 26K 17: R1 Cover HTML 96K 18: R2 Consolidated Balance Sheets HTML 144K 19: R3 Consolidated Balance Sheets (Parenthetical) HTML 62K 20: R4 Consolidated Statements of Operations HTML 143K 21: R5 Consolidated Statements of Comprehensive Loss HTML 43K 22: R6 Consolidated Statements of Series A Redeemable HTML 96K Convertible Preferred Stock and Shareholders' Equity 23: R7 Consolidated Statements of Cash Flows HTML 133K 24: R8 Organization, Description of the Business and HTML 48K Liquidity 25: R9 Summary of Significant Accounting Policies HTML 224K 26: R10 Business Combinations HTML 75K 27: R11 Right-Of-Use and Financing Lease Assets, Net, HTML 40K Machinery and Equipment, Net, and Construction in Progress 28: R12 Intangible Assets, Net HTML 51K 29: R13 Bank Loan HTML 40K 30: R14 Commitments and Contingencies HTML 107K 31: R15 Series A Redeemable Convertible Preferred Stock HTML 86K and Shareholders? Equity 32: R16 Stock-Based Compensation HTML 128K 33: R17 Income Taxes HTML 81K 34: R18 Related Party Transactions HTML 62K 35: R19 Co-Development Agreement with Life Technologies HTML 28K Corporation 36: R20 Discontinued Operations of Razor HTML 68K 37: R21 Subsequent Events HTML 46K 38: R22 Summary of Significant Accounting Policies HTML 281K (Policies) 39: R23 Summary of Significant Accounting Policies HTML 112K (Tables) 40: R24 Business Combinations (Tables) HTML 59K 41: R25 Right-Of-Use and Financing Lease Assets, Net, HTML 34K Machinery and Equipment, Net, and Construction in Progress (Tables) 42: R26 Intangible Assets, Net (Tables) HTML 46K 43: R27 Commitments and Contingencies (Tables) HTML 63K 44: R28 Stock-Based Compensation (Tables) HTML 88K 45: R29 Income Taxes (Tables) HTML 65K 46: R30 Discontinued Operations of Razor (Tables) HTML 63K 47: R31 Organization, Description of the Business and HTML 56K Liquidity (Details Narrative) 48: R32 Schedule of Fair Value Measurement of Financial HTML 48K Assets and Liabilities (Details) 49: R33 Schedule of Disaggregation of Revenue (Details) HTML 31K 50: R34 Schedule of Concentration of Risk (Details) HTML 34K 51: R35 Schedule of Consolidated Revenues Generated by HTML 36K Unaffiliated Customers (Details) 52: R36 Schedule of Percentage of Consolidated Revenues HTML 39K Attributable to Geographical Locations (Details) 53: R37 Schedule of Common Stock Computation of Diluted HTML 104K Net Loss Per Share of Common Stock (Details) 54: R38 Summary of Significant Accounting Policies HTML 127K (Details Narrative) 55: R39 Schedule of Fair Value of Contingent Consideration HTML 43K Liability (Details) 56: R40 Schedule of Contingent Consideration, Measured at HTML 37K Fair Value (Details) 57: R41 Business Combinations (Details Narrative) HTML 67K 58: R42 Schedule of Right-of-use and Financing Lease HTML 38K Assets, Machinery and Equipment, Net, and Construction in Progress (Details) 59: R43 Right-Of-Use and Financing Lease Assets, Net, HTML 36K Machinery and Equipment, Net, and Construction in Progress (Details Narrative) 60: R44 Schedule of Intangible Assets, Net (Details) HTML 44K 61: R45 Schedule of Intangible Assets Future Amortization HTML 31K Expense (Details) 62: R46 Intangible Assets, Net (Details Narrative) HTML 36K 63: R47 Bank Loan (Details Narrative) HTML 52K 64: R48 Schedule of Supplemental Balance Sheet Information HTML 60K Related to Operating and Financing Leases (Details) 65: R49 Schedule of Future Minimum Lease Commitments for HTML 55K Operating and Financing Leases (Details) 66: R50 Schedule of Supplemental Cash Flow Information HTML 31K Related to Operating and Financing Lease (Details) 67: R51 Commitments and Contingencies (Details Narrative) HTML 77K 68: R52 Series A Redeemable Convertible Preferred Stock HTML 197K and Shareholders? Equity (Details Narrative) 69: R53 Summary of Stock Option Activity (Details) HTML 108K 70: R54 Schedule of Assumptions Used to Calculate Fair HTML 34K Value of Stock Options (Details) 71: R55 Summary of Stock-based Compensation Expense HTML 38K (Details) 72: R56 Stock-Based Compensation (Details Narrative) HTML 127K 73: R57 Schedule of Components of Deferred Tax Assets and HTML 62K Liabilities (Details) 74: R58 Schedule of Income Tax Reconciliation (Details) HTML 52K 75: R59 Schedule of Unrecognized Tax Benefit (Details) HTML 33K 76: R60 Income Taxes (Details Narrative) HTML 66K 77: R61 Related Party Transactions (Details Narrative) HTML 136K 78: R62 Co-Development Agreement with Life Technologies HTML 26K Corporation (Details Narrative) 79: R63 Schedule of Discontinued Operations (Details) HTML 46K 80: R64 Schedule of Assets and Liabilities Discontinued HTML 70K Operations (Details) 81: R65 Discontinued Operations of Razor (Details HTML 48K Narrative) 82: R66 Subsequent Events (Details Narrative) HTML 60K 84: XML IDEA XML File -- Filing Summary XML 149K 87: XML XBRL Instance -- form10-k_htm XML 2.23M 83: EXCEL IDEA Workbook of Financial Report Info XLSX 199K 13: EX-101.CAL XBRL Calculations -- ocx-20231231_cal XML 239K 14: EX-101.DEF XBRL Definitions -- ocx-20231231_def XML 994K 15: EX-101.LAB XBRL Labels -- ocx-20231231_lab XML 1.54M 16: EX-101.PRE XBRL Presentations -- ocx-20231231_pre XML 1.27M 12: EX-101.SCH XBRL Schema -- ocx-20231231 XSD 199K 85: JSON XBRL Instance as JSON Data -- MetaLinks 566± 848K 86: ZIP XBRL Zipped Folder -- 0001493152-24-014720-xbrl Zip 511K
Exhibit 32.1
CERTIFICATIONS PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Annual Report on Form 10-K of Oncocyte Corporation (the “Company”) for the year ended December 31, 2023 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), we, Josh Riggs, President and Chief Executive Officer of the Company, and James Liu, Controller, Principal Accounting Officer and interim Principal Financial Officer of the Company, certify pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:
1 | The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and |
2. | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
Date: April 15, 2024
/s/ Josh Riggs | |
Josh Riggs | |
President and Chief Executive Officer (Principal Executive Officer) |
|
/s/ James Liu | |
James Liu | |
Controller, Principal Accounting Officer and interim Principal Financial Officer (Principal Financial Officer) |
This ‘10-K’ Filing | Date | Other Filings | ||
---|---|---|---|---|
Filed as of: | 4/16/24 | |||
Filed on: | 4/15/24 | 4, SC 13D/A | ||
For Period end: | 12/31/23 | NT 10-K | ||
List all Filings |
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 5/15/24 Oncocyte Corp. 10-Q 3/31/24 73:8.8M M2 Compliance LLC/FA 5/10/24 Oncocyte Corp. S-3 5:378K M2 Compliance LLC/FA |